机构：[1]Department of Urology and Institute of Urology, West China Hospital, Sichuan University, Chengdu, China四川大学华西医院[2]West China School of Medicine, Sichuan University, Chengdu, China四川大学华西医院[3]Department of Pathology, West China Hospital, Sichuan University,Chengdu, China四川大学华西医院[4]Department of Urology and Institute of Urology, West China Hospital, Sichuan University, Chengdu, China四川大学华西医院
This work was supported by the National Natural Science Foundation of China (Grant number: 81500522) and Science & Technology Department of Sichuan Province (Grant number: 2020YFS0090,
2020YFS0046).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2024]版：
无
最新[2023]版：
大类|3 区医学
小类|3 区外科
第一作者：
第一作者机构：[1]Department of Urology and Institute of Urology, West China Hospital, Sichuan University, Chengdu, China[2]West China School of Medicine, Sichuan University, Chengdu, China
通讯作者：
通讯机构：[4]Department of Urology and Institute of Urology, West China Hospital, Sichuan University, Chengdu, China[*1]Department of Urology and Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China
推荐引用方式(GB/T 7714)：
Ye Jianjun,Zhang Mengni,Bao Yige.Discordance of HER2 expression in primary and recurrent/metastatic urothelial carcinoma in the upper tract[J].Asian Journal Of Surgery.2024,47(9):3928-3929.doi:10.1016/j.asjsur.2024.04.161.
APA：
Ye Jianjun,Zhang Mengni&Bao Yige.(2024).Discordance of HER2 expression in primary and recurrent/metastatic urothelial carcinoma in the upper tract.Asian Journal Of Surgery,47,(9)
MLA：
Ye Jianjun,et al."Discordance of HER2 expression in primary and recurrent/metastatic urothelial carcinoma in the upper tract".Asian Journal Of Surgery 47..9(2024):3928-3929
